Corcept Therapeutics (CORT) Competitors $72.27 +0.79 (+1.10%) Closing price 03:59 PM EasternExtended Trading$73.28 +1.02 (+1.41%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT vs. ANVS, RPRX, JAZZ, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIXShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector. Corcept Therapeutics vs. Its Competitors Annovis Bio Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Do insiders & institutionals believe in CORT or ANVS? 93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend CORT or ANVS? Corcept Therapeutics currently has a consensus target price of $134.50, suggesting a potential upside of 86.11%. Annovis Bio has a consensus target price of $18.00, suggesting a potential upside of 603.40%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, CORT or ANVS? Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$675.04M11.28$141.21M$1.1363.95Annovis BioN/AN/A-$24.59M-$2.16-1.18 Which has more risk and volatility, CORT or ANVS? Corcept Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Is CORT or ANVS more profitable? Corcept Therapeutics has a net margin of 18.51% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 20.10% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics18.51% 20.10% 16.20% Annovis Bio N/A -300.56%-193.50% Does the media favor CORT or ANVS? In the previous week, Corcept Therapeutics had 21 more articles in the media than Annovis Bio. MarketBeat recorded 23 mentions for Corcept Therapeutics and 2 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.52 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 11 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCorcept Therapeutics beats Annovis Bio on 11 of the 14 factors compared between the two stocks. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.61B$2.41B$5.45B$9.67BDividend YieldN/A1.78%3.99%4.14%P/E Ratio63.9520.1830.0425.01Price / Sales11.28442.70377.6078.24Price / Cash56.78165.0335.9458.58Price / Book11.984.128.135.68Net Income$141.21M$31.61M$3.25B$265.58M7 Day Performance4.74%0.29%1.09%2.50%1 Month Performance6.03%2.27%2.75%1.87%1 Year Performance112.12%4.42%28.40%24.05% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.6518 of 5 stars$72.27+1.1%$134.50+86.1%+109.9%$7.61B$675.04M63.95300Insider TradeANVSAnnovis Bio1.4729 of 5 stars$2.94+1.7%$18.00+512.2%-67.7%$57.30MN/A-1.363News CoverageUpcoming EarningsRPRXRoyalty Pharma4.9328 of 5 stars$37.06+1.1%$49.00+32.2%+35.8%$20.84B$2.26B20.0380Earnings ReportJAZZJazz Pharmaceuticals4.3014 of 5 stars$117.38-0.7%$181.64+54.7%-0.2%$7.10B$4.07B15.652,800Trending NewsEarnings ReportAnalyst ForecastPRGOPerrigo4.635 of 5 stars$28.12-1.1%$33.00+17.4%-17.8%$3.87B$4.37B-21.478,379News CoverageEarnings ReportAnalyst ForecastSUPNSupernus Pharmaceuticals1.8028 of 5 stars$33.41-0.5%$36.00+7.8%+29.9%$1.87B$668.00M30.10580Analyst ForecastPCRXPacira BioSciences3.0465 of 5 stars$22.05-2.2%$27.00+22.4%+6.4%$1.02B$702.77M-9.67720Earnings ReportNKTRNektar Therapeutics4.1761 of 5 stars$23.65-5.4%$88.33+273.5%+22.9%$293.50M$98.43M-2.46220News CoverageEarnings ReportGap UpOMEROmeros3.8525 of 5 stars$4.15+8.4%$18.00+333.7%-8.9%$243.15MN/A-1.57210Gap UpHigh Trading VolumeASMBAssembly Biosciences3.7518 of 5 stars$19.50+5.1%$33.00+69.2%+68.1%$148.98M$28.52M-3.13100Earnings ReportCPIXCumberland Pharmaceuticals1.0262 of 5 stars$3.48-1.1%N/A+121.6%$52.06M$37.87M-13.9280Earnings ReportGap Down Related Companies and Tools Related Companies Annovis Bio Competitors Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CORT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
